Core Viewpoint - ModivCare reported a significant quarterly loss of $1.71 per share, which was much worse than the Zacks Consensus Estimate of a loss of $0.34, indicating a substantial earnings surprise of -402.94% [1] Financial Performance - The company posted revenues of $650.65 million for the quarter ended March 2025, slightly exceeding the Zacks Consensus Estimate by 0.96%, but down from $684.45 million in the same quarter last year [2] - Over the last four quarters, ModivCare has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates two times [2] Stock Performance - ModivCare shares have declined approximately 88.6% since the beginning of the year, contrasting sharply with the S&P 500's decline of only -4.3% [3] Future Outlook - The company's earnings outlook is critical for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.06 on revenues of $653.77 million, and for the current fiscal year, it is -$0.16 on revenues of $2.64 billion [7] Industry Context - The Medical Services industry, to which ModivCare belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Another company in the same industry, HealthEquity, is expected to report quarterly earnings of $0.81 per share, reflecting a year-over-year increase of 1.3% [9]

Core Viewpoint - Globalstar reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -42.86% [1] Financial Performance - The company posted revenues of $60.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.92%, but showing an increase from $56.48 million year-over-year [2] - Over the last four quarters, Globalstar has not surpassed consensus EPS estimates, although it has topped consensus revenue estimates three times [2] Stock Performance - Globalstar shares have declined approximately 35.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] Future Outlook - The company's earnings outlook will be crucial for stock performance, with current consensus EPS estimates at -$0.06 for the coming quarter and -$0.20 for the current fiscal year, alongside expected revenues of $65.3 million and $268.55 million respectively [7] - The Zacks Rank for Globalstar is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Satellite and Communication industry is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting that the industry's outlook could significantly impact Globalstar's stock performance [8]

Core Insights - Information Services Group (ISG) reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing a significant increase from $0.01 per share a year ago, resulting in an earnings surprise of 16.67% [1] - The company achieved revenues of $59.58 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.72%, although this represents a decline from year-ago revenues of $64.27 million [2] - ISG shares have increased approximately 18.3% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Outlook - The future performance of ISG's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, which includes current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $0.06 on revenues of $59.51 million, and for the current fiscal year, it is $0.27 on revenues of $241.16 million [7] Industry Context - The Consulting Services industry, to which ISG belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that ISG's stock may outperform the market based on its favorable estimate revisions trend [5][6]

Company Performance - GrowGeneration reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.14 per share a year ago, indicating a negative earnings surprise of -14.29% [1] - The company posted revenues of $35.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 10.22%, and down from year-ago revenues of $47.89 million [2] - Over the last four quarters, GrowGeneration has not surpassed consensus EPS estimates and has topped consensus revenue estimates only twice [2] Stock Performance - GrowGeneration shares have declined approximately 33.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $46.17 million, and for the current fiscal year, it is -$0.43 on revenues of $172.71 million [7] Industry Outlook - The Agriculture - Products industry, to which GrowGeneration belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - VAREX IMAGING reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and up from $0.16 per share a year ago, representing an earnings surprise of 85.71% [1] - The company posted revenues of $212.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.93%, compared to year-ago revenues of $206.2 million [2] - Over the last four quarters, VAREX IMAGING has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - VAREX IMAGING shares have declined approximately 44% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $207.93 million, and for the current fiscal year, it is $0.54 on revenues of $824.37 million [7] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact VAREX IMAGING's stock performance [5][6]

Core Insights - Rumble Inc. reported a quarterly loss of $0.12 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.11, but an improvement from a loss of $0.15 per share a year ago [1] - The company generated revenues of $23.71 million for the quarter, exceeding the Zacks Consensus Estimate by 2.81% and showing growth from $17.73 million year-over-year [2] - Rumble Inc. shares have declined approximately 41.6% year-to-date, contrasting with the S&P 500's decline of 4.3% [3] Financial Performance - The company has not surpassed consensus EPS estimates in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $25.35 million, and for the current fiscal year, it is -$0.35 on revenues of $109.9 million [7] Market Outlook - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Internet - Software industry, to which Rumble Inc. belongs, is ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Theravance Biopharma reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and compared to a loss of $0.09 per share a year ago, indicating a significant earnings surprise of -54.55% [1] - The company posted revenues of $15.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.20%, but showing an increase from year-ago revenues of $14.5 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Outlook - Theravance Bio shares have increased by approximately 6.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $17.1 million, and for the current fiscal year, it is $0.08 on revenues of $96.9 million [7] - The estimate revisions trend for Theravance Bio is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Theravance Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Cytek Biosciences reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and compared to a loss of $0.05 per share a year ago, indicating a significant earnings surprise of -125% [1] - The company posted revenues of $41.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.07%, and down from $44.86 million in the same quarter last year [2] - Over the last four quarters, Cytek has surpassed consensus EPS estimates two times and topped revenue estimates just once [2] Stock Performance - Cytek Biosciences shares have declined approximately 42.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $48.5 million, and for the current fiscal year, it is -$0.07 on revenues of $205.91 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cytek's stock performance [5]

Core Viewpoint - Fidus Investment (FDUS) reported quarterly earnings of $0.54 per share, exceeding the Zacks Consensus Estimate of $0.53 per share, but down from $0.59 per share a year ago, indicating a slight earnings surprise of 1.89% [1][2] Financial Performance - The company achieved revenues of $36.5 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.04% and showing an increase from $34.65 million year-over-year [2] - Over the last four quarters, Fidus Investment has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Fidus Investment shares have declined approximately 10.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.53 on revenues of $36.03 million, while for the current fiscal year, the estimate is $2.14 on revenues of $147.18 million [7] - The trend of estimate revisions for Fidus Investment has been favorable leading up to the earnings release [6] Industry Context - The Financial - SBIC & Commercial Industry, to which Fidus Investment belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Fidus Investment may be influenced by the overall outlook for the industry [8]

Company Performance - Natera reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and an improvement from a loss of $0.56 per share a year ago, representing an earnings surprise of 15.25% [1] - The company posted revenues of $501.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 13.19%, and showing a significant increase from year-ago revenues of $367.74 million [2] - Natera has surpassed consensus EPS estimates in all four of the last quarters [2] Stock Outlook - The immediate price movement of Natera's stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - Natera shares have increased by approximately 1.1% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $460.85 million, and for the current fiscal year, it is -$2.02 on revenues of $1.92 billion [7] - The estimate revisions trend for Natera is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Services industry, to which Natera belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, IceCure Medical Ltd. (ICCM), is expected to report a quarterly loss of $0.08 per share, with revenues projected at $0.75 million, reflecting a 1.4% increase from the year-ago quarter [9]